All News

CV,risk,MI,heart,cardiac

Turning the Corner on CV Risk in Rheumatoid Arthritis

d Richard Conway, MBBChBAO, PhD

Cardiovascular (CV) disease remains the leading cause of mortality in rheumatoid arthritis (RA). A number of studies progressed our knowledge in the session Rheumatoid arthritis - comorbidity and clinical aspects – I on Thursday at EULAR 2021.

Read Article
EULAR,poster

EULAR 2021 – Day 1 Report

d Jack Cush, MD

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Read Article
EULAR,Podcast,2021

EULAR 2021 - Day 1 Podcasts

d Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 1 broadcasts below.



You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com



Listen by Clicking below:



Day 1a

Read Article
Leave my MTX alone says pt & #rheumatologist if pt has chronic ILD. Acute pneumonia from MTX is NOT chronic ILD in RA @RheumNow @eular_org #EULAR2021 #BoehringerIngelheim RA ILD silent killer symposium https://t.co/IQTINuUpVq
Janet Pope Janetbirdope ( View Tweet)
Great talks on comorbidities in RA at #EULAR2021 today. What do we struggle most with in RA management? @RheumNow

Richard Conway RichardPAConway ( View Tweet)

RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it esp if older pt #EULAR2021 #BoehringerIngelheim symposium @RheumNow @eular_org https://t.co/be2Z7KMqpg
Janet Pope Janetbirdope ( View Tweet)
#POS0093 Collaborative registry studies are to be encouraged! BUT @k_lauper outlines the heterogenity between registries concerning #AE reporting - Jak-pot study - 18 registries with #RA patients on #tofacitinib - Rates of discontinuation vary across registry #EULAR2021 @RheumNow https://t.co/oczJAG8hzv
Paul Studenic Stiddyo ( View Tweet)
An original way of differentiating RA from PsA! The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of -HC 94% -RA 84% -PsA 89% and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310
Aurelie Najm AurelieRheumo ( View Tweet)
What is largest ⬆️ infection risk in RA? steroids, past infection, age, DM? Host factors & Prednisone are Impt. Piling up risk factors is often multiplied! Biggest risk of serious infection and is recurrent serious infection! #EULAR2021 Meet the expert AbbVie session @RheumNow https://t.co/6m0OfsNF1W
Janet Pope Janetbirdope ( View Tweet)
MUC5B promoter variant is associated with interstitial lung disease. Interactions with: 👉rheumatoid arthritis 👉 age 👉 sex Check this Finnish biobank study of 250,000 individuals presented by Antti Palömaki at the Plenary Abstracts Session Wed 02/06 16:15 >LC

ARD & RMD Open ARD_BMJ ( View Tweet)

Patients selected to maximise response & minimise adverse events in RA & PsA trials. What implications does this have when we interpret the data & try to apply in clinic? #EULAR2021 https://t.co/CocKlvjme4
Dr Irwin Lim _connectedcare ( View Tweet)
Worse dentition is associated with worse RA disease activity. And that's the tooth!🙄 from two big German cohorts @CallhoffJ POS0026 #EULAR2021 @RheumNow https://t.co/rjCQ6AtQzq
David Liew drdavidliew ( View Tweet)

ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
After this morning's great discussion at the #epidemiology interest group, Prof Nagy gives a summary of the @eular_org Definition of difficult-to-treat #RheumatoidArthritis at #EULAR2021, including a great summary of the elements and evidence behind the recommendation. https://t.co/imXECTlUbf
EMEUNET EMEUNET ( View Tweet)
Following this morning's excellent group discussion on #D2T #RA, Prof Nagy presents @eular_org Definition of #difficulttotreat RA at #EULAR2021 D2T disease, consider: 👉🏼Treatment history 👉🏼Presence of one of the below factors 👉🏼Mx of difficult signs/symptoms as per clinician https://t.co/xbtKuvjLw4
Mrinalini Dey DrMiniDey ( View Tweet)
Dr Lam presenting data on early RA and matched controls. T2T strategy led to no increased CV event risk over 5 years. Longer remission duration protective, higher baseline HAQ associated with higher risk @RheumNow #EULAR2021 Abstr#OP0103 https://t.co/MZdEoyWI64
Richard Conway RichardPAConway ( View Tweet)
We are truly blessed to live in an era when response to RA treatment is the norm. (our forefathers looking on jealously from their gold and pencillinamine towers!) real-world data from BIOBADASER registry OP0123 #EULAR2021 @RheumNow https://t.co/RuQkK1ZXZv
David Liew drdavidliew ( View Tweet)

tofa/bari in RA H2H vs TNFi comparative efficacy studies highlighted (more head-to-head studies please!) @karolinskainst OP0122 #EULAR2021 @RheumNow (also Swedish national registry data showed tofa/bari comparable to non-TNFi bDMARDs, but no photos allowed!) https://t.co/CUWlK2O94h

David Liew drdavidliew ( View Tweet)
VTE/VZV in baricitinib & tofacitinib seem unrelated to on-target effects. Is there VTE/VZV-related off-target culpable binding? Computer (AI) says no, but... bari binds PDE10A2 (an antipsychotic target), lab confirmed. Missing link to reduced pain? POS0091 #EULAR2021 @RheumNow https://t.co/uqYixHhW1z
David Liew drdavidliew ( View Tweet)
Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events. Why all the variation? (Until we sort that out, we'll struggle to assess JAKi post-marketing safety...) @k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw
David Liew drdavidliew ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.